🇺🇸 FDA
Patent

US 11680093

Monoclonal antibodies that specifically bind to matrilin 3 and their use

granted A61KA61K2039/505A61K47/6811

Quick answer

US patent 11680093 (Monoclonal antibodies that specifically bind to matrilin 3 and their use) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
40
CPC classes
A61K, A61K2039/505, A61K47/6811, A61K47/6843